A phase II trial of carboplatin, methotrexate and fluorouracil in fluorouracii-pretreated colorectal cancer

P. Pronzato, F. Botto, E. Ghio, F. Pensa, A. Tognoni, F. Vaira, A. Vigani, E. Neri

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

5-Fluorouracil and leucovorin combination is the most commonly applied chemotherapy treatment for colorectal cancer patients, both in the adjuvant setting and for advanced disease. Patients resistant or refractory to the 5- fluorouracil-leucovorin combination have been treated in this phase II trial with carboplatin plus methotrexate and fluorouracil in sequence. Twenty patients with measurable lesions from advanced colorectal cancer were entered in the trial. The treatment plan was carboplatin 300 mg/m 2 day 1, methotrexate 40 mg/m 2 day 1, fluorouracil 600 mg/m 2 day 2, every 21 days. Two patients with liver metastasis had a partial response. Median survival was 12 months (range 4-24). Toxicity was acceptable and no patient had to be hospitalized because of the treatment. in this set of patients activity of the new combination is marginal.

Original languageEnglish
Pages (from-to)254-257
Number of pages4
JournalJournal of Chemotherapy
Volume10
Issue number3
Publication statusPublished - 1998

Fingerprint

Carboplatin
Methotrexate
Fluorouracil
Colorectal Neoplasms
Leucovorin
Therapeutics
Neoplasm Metastasis
Drug Therapy
Survival
Liver

Keywords

  • 5-fluorouracil
  • Carboplatin
  • Colorectal cancer
  • Methotrexate

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)

Cite this

Pronzato, P., Botto, F., Ghio, E., Pensa, F., Tognoni, A., Vaira, F., ... Neri, E. (1998). A phase II trial of carboplatin, methotrexate and fluorouracil in fluorouracii-pretreated colorectal cancer. Journal of Chemotherapy, 10(3), 254-257.

A phase II trial of carboplatin, methotrexate and fluorouracil in fluorouracii-pretreated colorectal cancer. / Pronzato, P.; Botto, F.; Ghio, E.; Pensa, F.; Tognoni, A.; Vaira, F.; Vigani, A.; Neri, E.

In: Journal of Chemotherapy, Vol. 10, No. 3, 1998, p. 254-257.

Research output: Contribution to journalArticle

Pronzato, P, Botto, F, Ghio, E, Pensa, F, Tognoni, A, Vaira, F, Vigani, A & Neri, E 1998, 'A phase II trial of carboplatin, methotrexate and fluorouracil in fluorouracii-pretreated colorectal cancer', Journal of Chemotherapy, vol. 10, no. 3, pp. 254-257.
Pronzato, P. ; Botto, F. ; Ghio, E. ; Pensa, F. ; Tognoni, A. ; Vaira, F. ; Vigani, A. ; Neri, E. / A phase II trial of carboplatin, methotrexate and fluorouracil in fluorouracii-pretreated colorectal cancer. In: Journal of Chemotherapy. 1998 ; Vol. 10, No. 3. pp. 254-257.
@article{078e60db5d634621b7c93a0b6201fe17,
title = "A phase II trial of carboplatin, methotrexate and fluorouracil in fluorouracii-pretreated colorectal cancer",
abstract = "5-Fluorouracil and leucovorin combination is the most commonly applied chemotherapy treatment for colorectal cancer patients, both in the adjuvant setting and for advanced disease. Patients resistant or refractory to the 5- fluorouracil-leucovorin combination have been treated in this phase II trial with carboplatin plus methotrexate and fluorouracil in sequence. Twenty patients with measurable lesions from advanced colorectal cancer were entered in the trial. The treatment plan was carboplatin 300 mg/m 2 day 1, methotrexate 40 mg/m 2 day 1, fluorouracil 600 mg/m 2 day 2, every 21 days. Two patients with liver metastasis had a partial response. Median survival was 12 months (range 4-24). Toxicity was acceptable and no patient had to be hospitalized because of the treatment. in this set of patients activity of the new combination is marginal.",
keywords = "5-fluorouracil, Carboplatin, Colorectal cancer, Methotrexate",
author = "P. Pronzato and F. Botto and E. Ghio and F. Pensa and A. Tognoni and F. Vaira and A. Vigani and E. Neri",
year = "1998",
language = "English",
volume = "10",
pages = "254--257",
journal = "Journal of Chemotherapy",
issn = "1120-009X",
publisher = "Maney Publishing",
number = "3",

}

TY - JOUR

T1 - A phase II trial of carboplatin, methotrexate and fluorouracil in fluorouracii-pretreated colorectal cancer

AU - Pronzato, P.

AU - Botto, F.

AU - Ghio, E.

AU - Pensa, F.

AU - Tognoni, A.

AU - Vaira, F.

AU - Vigani, A.

AU - Neri, E.

PY - 1998

Y1 - 1998

N2 - 5-Fluorouracil and leucovorin combination is the most commonly applied chemotherapy treatment for colorectal cancer patients, both in the adjuvant setting and for advanced disease. Patients resistant or refractory to the 5- fluorouracil-leucovorin combination have been treated in this phase II trial with carboplatin plus methotrexate and fluorouracil in sequence. Twenty patients with measurable lesions from advanced colorectal cancer were entered in the trial. The treatment plan was carboplatin 300 mg/m 2 day 1, methotrexate 40 mg/m 2 day 1, fluorouracil 600 mg/m 2 day 2, every 21 days. Two patients with liver metastasis had a partial response. Median survival was 12 months (range 4-24). Toxicity was acceptable and no patient had to be hospitalized because of the treatment. in this set of patients activity of the new combination is marginal.

AB - 5-Fluorouracil and leucovorin combination is the most commonly applied chemotherapy treatment for colorectal cancer patients, both in the adjuvant setting and for advanced disease. Patients resistant or refractory to the 5- fluorouracil-leucovorin combination have been treated in this phase II trial with carboplatin plus methotrexate and fluorouracil in sequence. Twenty patients with measurable lesions from advanced colorectal cancer were entered in the trial. The treatment plan was carboplatin 300 mg/m 2 day 1, methotrexate 40 mg/m 2 day 1, fluorouracil 600 mg/m 2 day 2, every 21 days. Two patients with liver metastasis had a partial response. Median survival was 12 months (range 4-24). Toxicity was acceptable and no patient had to be hospitalized because of the treatment. in this set of patients activity of the new combination is marginal.

KW - 5-fluorouracil

KW - Carboplatin

KW - Colorectal cancer

KW - Methotrexate

UR - http://www.scopus.com/inward/record.url?scp=0031842670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031842670&partnerID=8YFLogxK

M3 - Article

C2 - 9669653

AN - SCOPUS:0031842670

VL - 10

SP - 254

EP - 257

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - 3

ER -